The authors review the role of enhancer of zeste homology 2 (EZH2) in regulating bone marrow MSC differentiation and the immune cell function in tumor microenvironment, summarize all types of existing EZH2 inhibitors and the main clinical trials, and propose relevant ideas for potential clinical applications.
[Critical Reviews in Oncology/Hematology]